ChemBridge Corporation and Collaborative Drug Discovery Announce Strategic Collaboration to Provide Diverse Chemical Libraries Together with Researchers Own Private Data
BURLINGAME, California, August 31, 2009 &mdash ChemBridge Corporation, a leading discovery chemistry company offering an extensive portfolio of discovery chemistry products and contract research services, has now made ten of their most popular screening libraries available to researchers via the Collaborative Drug Discovery (CDD) Public Access database. Now for the first time, researchers can access ChemBridge Libraries alongside a growing body of public data from leading vendors, researchers, scientific literature, and patent resources. CDD subscribers can access the data directly from their private groups, mining the libraries using their own private data to more effectively identify compounds of interest within the ChemBridge datasets, increasing the efficiency of identifying drug candidates. “The CDD database is an effective platform for biological and chemical data storage and mining, and knowing that a number of our client companies and research organizations are actively using the CDD database, we wanted to ensure that our clients could easily integrate ChemBridge screening library data into their workflow within the CDD database,” said Duncan Beniston, Executive Director Sales & Marketing, ChemBridge.
The libraries being offered include ChemBridge’s DIVERSetTM, a 50,000 diverse small molecule dataset covering a broad range of pharmacophore space , CNS-SetTM, containing 56,000 molecules with an increased probability of blood brain barrier penetration, as well as eight other libraries from ChemBridge’s impressive portfolio. In total, more than 600,000 ChemBridge molecules will be available through the CDD Database. “The CDD community for private access and the entire researcher community for public access both benefit when valuable new molecules and data are added to the database, such as the latest compounds available right off the shelf from ChemBridge,” says CDD CEO Barry Bunin, PhD, “and experimental and computational scientists with this new technology can view whole libraries and drill down to individual compounds from multiple data feeds. It is a new way of simultaneously interacting with lots of data from lots of collaborations.”
With the CDD database previously consisting of well over a million compounds, ChemBridge’s libraries join an impressive list of co-contributors. With the ongoing help of academic, non-profit, and industry contributors, CDD is continuously expanding the public database with both chemical and biological data. Collectively, these data sets and the software are being accessed by thousands of cutting edge researchers around the world. Anyone can register for free read-only access to these new and all public data sets on CDD’s website (www.collaborativedrug.com/register), read-and-write access (including the ability to archive, mine, and collaborate around private data and to import and export both private and public data) can be accessed following a free trial with full commercial access (contact: email@example.com). The compounds are available for testing hypotheses from ChemBridge (www.chembridge.com), additional molecules not in the public site can be ordered and the corresponding structures can also be archived in private sites and linked to biological activity data.
About Collaborative Drug Discovery, Inc.
Collaborative Drug Discovery, Inc. (CDD) – https://www.collaborativedrug.com – provides web-based software that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to “archive, mine, and collaborate”® around preclinical chemical and biological drug discovery data through a web-based interface. The software helps distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Unique collaboration features and CDD’s community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies.
About ChemBridge Corporation
ChemBridge Corporation, www.chembridge.com, is a leading global discovery chemistry company providing custom chemistry services, small molecule screening compound libraries and specialty building blocks for organic synthesis. ChemBridge is a San Diego based company with an impeccable 15 year track record of quality and deliverability and operates a state-of-the-art offshore discovery chemistry research site in Moscow, Russia. ChemBridge’s CRO business includes multi-year strategic alliances with major pharmaceutical companies as well as mid-size pharmaceutical and biotech companies. Over 500 pharmaceutical and biotech companies and universities worldwide have also taken advantage of ChemBridge’s portfolio of products, including its library of 10,000 specialty building blocks and 800,000 drug-like and lead-like small molecule screening compounds.
For further information please contact:
Barry Bunin, Ph.D.
President & CEO
Collaborative Drug Discovery (CDD)
1633 Bayshore Hwy, Suite 342
Burlingame, CA 94010
Executive Director, Sales & Marketing